risdiplam Archives - Knowledge Ecology International

KEI asks WHO to include risdiplam, treatment for Spinal Muscular Atrophy, on the Essential Medicines List (EML)

Posted on November 15, 2022 by KEI Staff

KEI has petitioned the World Health Organization (WHO) to include risdiplam, a drug to treat Spinal Muscular Atrophy (SMA), on its Essential Medicines List (EML), in a category for products that should be accessible if available at affordable prices. Risdiplam-EML-2022-KEI

KEI letter to Roche requesting voluntary license to patents on risdiplam, a treatment for Spinal Muscular Atrophy (SMA)

Posted on July 8, 2022 by James Love

This is a letter to Roche requesting a voluntary license to the patents on risdiplam, a treatment for Spinal Muscular Atrophy (SMA). KEI-Risdiplan-patent-license-request-8july2022

risdiplam

Risdiplam, originally developed under contract with the SMA Foundtion by PTC therapuetics and licensed to Roche for sale under the brand name Evrysdi, is a medication used to treat spinal muscular atrophy and the first oral medication approved to treat… Continue Reading →

risdiplam

KEI asks WHO to include risdiplam, treatment for Spinal Muscular Atrophy, on the Essential Medicines List (EML)

KEI letter to Roche requesting voluntary license to patents on risdiplam, a treatment for Spinal Muscular Atrophy (SMA)

risdiplam

Meta

Categories